TY  - BOOK
AU  - Arora, Aakriti 
AU  - Zaemes, Jacob 
TI  - Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
SN  - 2234-943X
PY  - 2023///
KW  - Automated
KW  - MedStar Washington Hospital Center
KW  - Hematology & Oncology Fellowship
KW  - Internal Medicine Residency
KW  - MedStar Georgetown University Hospital/MedStar Washington Hospital Center
KW  - Case Reports
N2  - Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B-RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment. Copyright © 2023 Arora, Zaemes, Ozdemirli and Kim
UR  - https://dx.doi.org/10.3389/fonc.2023.1134151
ER  -